Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

JAMA Oncology ◽  
2022 ◽  
Author(s):  
Guru Subramanian Guru Murthy ◽  
Soyoung Kim ◽  
Zhen-Huan Hu ◽  
Noel Estrada-Merly ◽  
Muhammad Bilal Abid ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Disease Free Survival ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Free Survival ◽  
Unrelated Donors ◽  
Matched Sibling ◽  
Disease Free

The Impact of Desferrioxamine Postallogeneic Hematopoietic Cell Transplantation in Relapse Incidence and Disease-Free Survival: A Retrospective Analysis

2010 ◽  
Vol 89 (4) ◽  
pp. 472-479 ◽  
Author(s):  
Panayotis Kaloyannidis ◽  
Evangelia Yannaki ◽  
Ioanna Sakellari ◽  
Ekaterini Bitzioni ◽  
Anastasia Athanasiadou ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Disease Free Survival ◽  
Hematopoietic Cell ◽  
Free Survival ◽  
The Impact ◽  
Disease Free

scholarly journals HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

2019 ◽  
Vol 3 (17) ◽  
pp. 2581-2585 ◽  
Author(s):  
Mohamad A. Meybodi ◽  
Wenhao Cao ◽  
Leo Luznik ◽  
Asad Bashey ◽  
Xu Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Meta Analysis ◽  
Hematopoietic Cell ◽  
Free Survival ◽  
Relative Contribution ◽  
Haploidentical Hematopoietic Cell Transplantation ◽  
Matched Sibling ◽  
Outcome Differences

Abstract HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases

Blood ◽  
2011 ◽  
Vol 117 (17) ◽  
pp. 4642-4650 ◽  
Author(s):  
Ansgar S. Schulz ◽  
Gerhard Glatting ◽  
Manfred Hoenig ◽  
Catharina Schuetz ◽  
Susanne A. Gatz ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Pilot Study ◽  
Confidence Interval ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Disease Free Survival ◽  
Reduced Intensity Conditioning ◽  
Free Survival ◽  
Disease Free ◽  
Reduced Intensity

AbstractTargeted irradiation of the bone marrow with radiolabeled monoclonal antibodies (radioimmunotherapy) represents a novel therapeutic approach with both myeloablative and antileukemic potential. In an open-label, single-center pilot study, 30 pediatric and adolescent patients undergoing hematopoietic cell transplantation for malignant (n = 16) and nonmalignant (n = 14) disorders received treatment with a 90Y-labeled anti-CD66 monoclonal antibody. Patients with a high risk of relapse (n = 7) received additional treatment with standard conditioning based on either total body irradiation or busulfan to intensify the antileukemic effect. In patients with comorbidities (n = 23), radioimmunotherapy was combined with a reduced-intensity conditioning regimen to reduce systemic toxicity. Preferential irradiation of the bone marrow was achieved in all patients. Nonrelapse mortality was 4 (13%) of 30 patients. In patients with malignant diseases, the probabilities of overall and disease-free survival at 2 years were 0.69 (95% confidence interval 0.37-0.87) and 0.46 (95% confidence interval 0.19-0.70), respectively. In patients with nonmalignant diseases, the probability of both overall and disease-free survival at 2 years was 0.94 (95% confidence interval 0.63-0.99). This pilot study demonstrates that radioimmunotherapy is effective in achieving myeloablation with low additional toxicity when used in combination with standard or reduced-intensity conditioning in young patients.

scholarly journals Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy

2020 ◽  
Vol 4 (19) ◽  
pp. 4798-4801
Author(s):  
Ibrahim Aldoss ◽  
Joo Y. Song ◽  
Peter T. Curtin ◽  
Stephen J. Forman
Keyword(s):  
Transplant Recipient ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Malignant Transformation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Myeloid Malignancy ◽  
Key Points

Key Points A patient with myelodysplastic syndrome was transplanted twice and developed clonally unrelated relapse each time in donor-derived cells. This case supports the concept that a leukemogenic marrow environment may predispose the transplant recipient to malignant transformation.

Sign in / Sign up

Export Citation Format

Share Document